Announced as Funding Competition Winner

RNS Number : 6971L

Oxford Biomedica PLC

14 August 2013

 

Oxford BioMedica Announced as Regenerative Medicine and Cell Therapy Funding Competition Winner by the UK's innovation agency, the Technology Strategy Board 

-- Funding to be received for the development of a novel therapeutic treatment to engineer corneas to resist graft rejection --

Oxford, UK - 14 August 2013: Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), the leading gene-based biopharmaceutical company, notes that the UK's innovation agency, the Technology Strategy Board (TSB) has announced that the Company has been selected as one of seven winners of a funding award under the 2013 Supporting Regenerative Medicines and Cell Therapies competition.  The funding will be used to fund the development of a novel therapeutic treatment to engineer corneas to resist graft rejection utilising Oxford BioMedica's proprietary LentiVector^® platform technology.  The funding award is subject to due diligence and final confirmation by the Technology Strategy Board and further details will be disclosed in due course.

-Ends-

For further information, please contact:
Oxford BioMedica plc: Lara Mott, Head of Investor Relations and Corporate Communications	Tel: [phone]
Media Enquiries: Mary-Jane Elliott/Matthew Neal Consilium Strategic Communications	Tel: [phone]

Notes to editors

1. About Oxford BioMedica^®

Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company's technology platform includes a highly efficient LentiVector^® gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, Oxford BioMedica has a broad pipeline with current partners and licensees including Sanofi, Pfizer, Novartis, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions, ImaginAb and Immune Design Corp. Further information is available at www.oxfordbiomedica.co.uk and www.oxbsolutions.co.uk.

2. LentiVector^® gene delivery technology

Oxford BioMedica's LentiVector^® gene delivery technology is one of the most advanced gene delivery systems currently available, which has many applications in product development and discovery research.  It is the system of choice for gene-based treatments addressing chronic and inherited diseases.  Oxford BioMedica has established a dominant intellectual property estate in the field of lentiviral-vector mediated gene delivery through its in-house research and from work conducted by the Company's co-founders at Oxford University.

3. The Technology Strategy Board

The Technology Strategy Board is the UK's innovation agency. Its goal is to accelerate economic growth by stimulating and supporting business-led innovation. Sponsored by the Department for Business, Innovation and Skills (BIS), the Technology Strategy Board brings together business, research and the public sector, supporting and accelerating the development of innovative products and services to meet market needs, tackle major societal challenges and help build the future economy. For more information please visit www.innovateuk.org.

 

END

 

 

MSCEAFPLFSDDEFF